334 related articles for article (PubMed ID: 34601002)
1. Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation.
Pyun DH; Kim TJ; Park SY; Lee HJ; Abd El-Aty AM; Jeong JH; Jung TW
Mol Cell Endocrinol; 2021 Dec; 538():111464. PubMed ID: 34601002
[TBL] [Abstract][Full Text] [Related]
2. Resolvin D3 improves the impairment of insulin signaling in skeletal muscle and nonalcoholic fatty liver disease through AMPK/autophagy-associated attenuation of ER stress.
Oh H; Cho W; Abd El-Aty AM; Bayram C; Jeong JH; Jung TW
Biochem Pharmacol; 2022 Sep; 203():115203. PubMed ID: 35948170
[TBL] [Abstract][Full Text] [Related]
3. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
4. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
[No Abstract] [Full Text] [Related]
5. Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis.
Simão AL; Afonso MB; Rodrigues PM; Gama-Carvalho M; Machado MV; Cortez-Pinto H; Rodrigues CMP; Castro RE
J Mol Med (Berl); 2019 Aug; 97(8):1113-1126. PubMed ID: 31139863
[TBL] [Abstract][Full Text] [Related]
6. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
7. Protopanaxadiol ameliorates NAFLD by regulating hepatocyte lipid metabolism through AMPK/SIRT1 signaling pathway.
Li Y; Liu Y; Chen Z; Tang K; Yang L; Jiang Y; Wang J; Huang P; Wang J; Zheng P; Song H
Biomed Pharmacother; 2023 Apr; 160():114319. PubMed ID: 36724639
[TBL] [Abstract][Full Text] [Related]
8. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
[TBL] [Abstract][Full Text] [Related]
9. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
10. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
11. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
12. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet.
Liou CJ; Lee YK; Ting NC; Chen YL; Shen SC; Wu SJ; Huang WC
Cells; 2019 May; 8(5):. PubMed ID: 31083505
[TBL] [Abstract][Full Text] [Related]
13. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
14. BAIBA attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK-PPARδ-dependent pathway in mice.
Jung TW; Hwang HJ; Hong HC; Yoo HJ; Baik SH; Choi KM
Diabetologia; 2015 Sep; 58(9):2096-105. PubMed ID: 26105792
[TBL] [Abstract][Full Text] [Related]
15. Activation of the AMPK/Sirt1 pathway by a leucine-metformin combination increases insulin sensitivity in skeletal muscle, and stimulates glucose and lipid metabolism and increases life span in Caenorhabditis elegans.
Banerjee J; Bruckbauer A; Zemel MB
Metabolism; 2016 Nov; 65(11):1679-1691. PubMed ID: 27456392
[TBL] [Abstract][Full Text] [Related]
16. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
17. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
18. Combination of luteolin and lycopene effectively protect against the "two-hit" in NAFLD through Sirt1/AMPK signal pathway.
Zhu Y; Liu R; Shen Z; Cai G
Life Sci; 2020 Sep; 256():117990. PubMed ID: 32574665
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice.
Shiota A; Shimabukuro M; Fukuda D; Soeki T; Sato H; Uematsu E; Hirata Y; Kurobe H; Maeda N; Sakaue H; Masuzaki H; Shimomura I; Sata M
Cardiovasc Diabetol; 2012 Nov; 11():139. PubMed ID: 23137106
[TBL] [Abstract][Full Text] [Related]
20. Maresin 1 attenuates NAFLD by suppression of endoplasmic reticulum stress via AMPK-SERCA2b pathway.
Jung TW; Kim HC; Abd El-Aty AM; Jeong JH
J Biol Chem; 2018 Mar; 293(11):3981-3988. PubMed ID: 29414781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
